User Experiences of Pharmacogenomic Testing and Opinions among Psychiatry Patients

Author:

Virelli Catherine R.12,Ebrahimi Mahbod13,Mohiuddin Ayeshah G.12,Tomasi Julia13,Lisoway Amanda J.13,Herbert Deanna1,Marshe Victoria S.4,Kidd Sean A.135,Ferenbok Joseph6,Kennedy James L.135

Affiliation:

1. Tanenbaum Centre for Pharmacogenetics, Campbell Family Mental Health Research Institute, Centre for Addiction and Mental Health, Toronto, ON M6J 1H4, Canada

2. Translational Research Program, University of Toronto, Toronto, ON M5S 1A8, Canada

3. Institute of Medical Science, University of Toronto, Toronto, ON M5S 1A8, Canada

4. Department of Neurology, Columbia University, New York, NY 10027, USA

5. Department of Psychiatry, University of Toronto, Toronto, ON M5S 1A8, Canada

6. Laboratory Medicine and Pathobiology, University of Toronto, Toronto, ON M5S 1A8, Canada

Abstract

Pharmacogenomic testing (PGx) is a tool used to guide physicians in selecting an optimal medication for clients based on their genetic profile. The objective of this qualitative study is to understand patients’ experiences with PGx testing as well as their opinions regarding the clinical adoption of such tests in psychiatry. A focus group was conducted to assess the needs of clients who had experience using a PGx test. Participants were recruited from a large study on PGx testing that offered physicians an opportunity to use PGx reports to guide psychotropic prescriptions. The focus group discussions were recorded, transcribed, and coded using NVivo to identify core themes. A total of 11 people participated in the focus group. Our analysis revealed that many participants were in favour of implementing PGx testing in psychiatric practice, and all expressed important considerations for patient-centred optimization of PGx testing. The main themes captured were: education and awareness among clinicians, cost considerations, PGx results-sharing and accessibility, and prospective benefits. The results of this study suggest that patients are keen to see PGx testing in widespread clinical care, but they report important opportunities to improve knowledge mobilization of PGx testing.

Funder

The Larry and Judy Tanenbaum Family Foundation

Publisher

MDPI AG

Subject

Medicine (miscellaneous)

Reference34 articles.

1. The ‘Delayed Onset’ of Antipsychotic Action—An Idea Whose Time Has Come and Gone;Agid;J. Psychiatry Neurosci.,2006

2. Acute and longer-term outcomes in depressed outpatients requiring one or several treatment steps: A STAR*D report;Rush;Am. J. Psychiatry,2006

3. Medication nonadherence and psychiatry;Chapman;Curr. Opin. Psychiatry,2013

4. Perspectives on medication nonadherence in psychiatric patients;Mert;Patient Prefer. Adherence,2015

5. Pharmacogenomic Testing and Depressive Symptom Remission: A Systematic Review and Meta-Analysis of Prospective, Controlled Clinical Trials;Brown;Clin. Pharmacol. Ther.,2022

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3